Abstract | OBJECTIVE: METHODS: Splenic-derived T cells and bone marrow-derived dendritic cells (DCs) were cultured, activated, and treated daily with vehicle or JHU-083. Proliferation and activation were measured via flow cytometry and IncuCyte live cell analysis. C57BL/6 mice were immunized for EAE. Vehicle or JHU-083 was administered orally every other day either from the time of immunization in the prevention paradigm or from the time of disease onset in the treatment paradigm. Disease scores and body weight were monitored. In the treatment paradigm, cognition was evaluated using the Barnes maze test. RESULTS: JHU-083 selectively inhibits T-cell proliferation and decreases T-cell activation, with no effect on DCs. In vivo, orally administered JHU-083 significantly decreases EAE severity in both prevention and treatment paradigms and reverses EAE-induced cognitive impairment. CONCLUSIONS: JHU-083, a well-tolerated, brain penetrable glutamine antagonist, is a promising novel treatment for both the physical and cognitive deficits of MS.
|
Authors | Kristen R Hollinger, Matthew D Smith, Leslie A Kirby, Eva Prchalova, Jesse Alt, Rana Rais, Peter A Calabresi, Barbara S Slusher |
Journal | Neurology(R) neuroimmunology & neuroinflammation
(Neurol Neuroimmunol Neuroinflamm)
Vol. 6
Issue 6
(11 2019)
ISSN: 2332-7812 [Electronic] United States |
PMID | 31467038
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. |
Chemical References |
- Azo Compounds
- Caproates
- JHU083
- Glutamine
|
Topics |
- Animals
- Azo Compounds
(pharmacology)
- Behavior, Animal
(drug effects)
- Caproates
(pharmacology)
- Cells, Cultured
- Cognitive Dysfunction
(drug therapy, etiology)
- Encephalomyelitis, Autoimmune, Experimental
(complications, drug therapy)
- Female
- Glutamine
- Male
- Mice
- Mice, Inbred C57BL
- Multiple Sclerosis
(complications, drug therapy)
|